




## Ulipristal

Revised: December 3, 2018.

CASRN: 159811-51-5



## Drug Levels and Effects

### Summary of Use during Lactation

Ulipristal is a selective progesterone receptor modulator used in a single dose as an emergency postcoital contraceptive. No information is available on the clinical use of ulipristal during breastfeeding. The manufacturer recommends avoiding use of ulipristal acetate during breastfeeding; others recommend withholding breastfeeding for 24 hours after use, based on the low levels in breastmilk.[1][2]

### Drug Levels

Ulipristal acetate is metabolized to mono- and di-demethylated metabolites by CYP3A4. Monodemethyl-ulipristal is pharmacologically active.

*Maternal Levels.* The breastmilk of 12 lactating women following administration of ulipristal (dosage not stated, but presumably 30 mg) was collected in 24-hour increments to measure the concentrations of ulipristal acetate and monodemethyl-ulipristal acetate in breastmilk. The mean daily concentrations of ulipristal acetate in breastmilk were 22.7 mcg/L (0-24 hours), 2.96 mcg/L (24-48 hours), 1.56 mcg/L (48-72 hours), 1.04 ng/mL (72-96 hours), and 0.69 mcg/L (96-120 hours). The mean daily concentrations of monodemethyl-ulipristal acetate in breastmilk were 4.49 mcg/L (0-24 hours), 0.62 mcg/L (24-48 hours), 0.28 mcg/L (48-72 hours), 0.17 mcg/L (72-96 hours), and 0.10 mcg/L (96-120 hours).[2] Using these data, a fully breastfed infant would receive about 4.1 mcg/kg of drug plus active metabolite on the first day and a total of 5.2 mcg/kg over 5 days. Assuming a 30 mg dose and an average maternal weight of 60 kg, the infant would receive a weight-adjusted dosage of 0.8% of drug plus active metabolite on the first day and a total of 1% of the maternal dose over the 5-day period.

*Infant Levels.* Relevant published information was not found as of the revision date.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Alternate Drugs to Consider

Intrauterine Copper Contraceptive, Oral Levonorgestrel

## References

1. Sridhar A, Salcedo J. Optimizing maternal and neonatal outcomes with postpartum contraception: Impact on breastfeeding and birth spacing. *Matern Health Neonatol Perinatol.* 2017;3:1. PubMed PMID: 28101373.
2. Afaxys Inc. Ella Package Insert. 2014.

## Substance Identification

### Substance Name

Ulipristal

### CAS Registry Number

159811-51-5

### Drug Class

Breast Feeding

Lactation

Contraceptive Agents

Contraceptives, Postcoital

Contraceptive Agents, Female